FCCC LOGO Faculty Publications
Oostendorp RL , Loftiss J , Goel S , Smith DA , Dar MM , Witteveen PO , Cohen RB , Lewis LD , Kurian S , Patnaik A , Rosing H , Beijnen JH , Voest EE , Burris H , Schellens JHM
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors
International Journal of Clinical Pharmacology and Therapeutics. 2009 Mar;47(3) :195-206
Back to previous list
Abstract
Objective: The aims of this Study were to investigate the bioequivalence of a new oral topotecan formulation (i.e., proposed commercial formulation) relative to the Current oral formulation (formulation used in previous clinical trials), the effect of food oil the absorption and disposition of the new oral topotecan and its safety and tolerability in patients with advanced solid tumors. Patients and methods: This was a multi-center, pharmacological Phase I, multiple-dose, randomized, open-label, cross-over bioequivalence study. In the bioequivalence part, 85 patients were randomized to receive either a 4 mg (4 x 1 mg) dose of the new or current formulation on Days 1 or 8. In the food-effect part, 23 patients received a 4 mg (4 x 1 mg) dose of the new formulation in a fasted and fed state. Total topotecan and topotecan lactone were determined and pharmacokinetic data were analyzed by non-compartmental method. Results: Bioequivalence was demonstrated as the 90% confidence intervals of the ratio of the new to Current formulation for both the area under the plasma concentration-time Curve (AUC) and the maximal drug concentration (C-max) for topotecan lactone were contained within the 0.8 - 1.25 boundary. The AUC and C-max were similar in the fed and fasted state whilst food delayed the t(max) for topotecan lactone and total topotecan. Safety data were collected Oil all Subjects enrolled (n = 108) and were consistent with observations from previous Studies of oral topotecan. All subjects experienced at least one adverse event, the majority of which were graded as mild to moderate in severity. Conclusion: The new oral topotecan formulation demonstrated bioequivalence to the current formulation and demonstrated it call be administered to patients with solid tumors in the fed or fasted state with similar systemic exposure.
Notes
Oostendorp, R. L. Loftiss, J. Goel, S. Smith, D. A. Dar, M. M. Witteveen, P. O. Cohen, R. B. Lewis, L. D. Kurian, S. Patnaik, A. Rosing, H. Beijnen, J. H. Voest, E. E. Burris, H. Schellens, J. H. M. DUSTRI-VERLAG DR KARL FEISTLE 417OP